Table 3.
Multivariable survival analysis of breast cancer-specific survival and overall survival in metastatic breast cancer.
| OS | Model 1 HR (95% CI) | Model 2 HR (95% CI) | Model 3 HR (95% CI) | Model 4 HR (95% CI) | Model 5 HR (95% CI) |
|---|---|---|---|---|---|
| Unmarried | Reference | Reference | Reference | Reference | Reference |
| Married† | 0.695(0.668–0.723)* | 0.784(0.752–0.817)* | 0.778(0.747–0.811)* | 0.808(0.775–0.842)* | 0.810(0.777–0.844)* |
| Married‡ | 0.697(0.665–0.732)* | 0.779(0.741–0.818)* | 0.762(0.725–0.800)* | 0.794(0.755–0.834)* | 0.794(0.756–0.835)* |
| BCSS | SHR (95% CI) | SHR (95% CI) | SHR (95% CI) | SHR (95% CI) | SHR (95% CI) |
|---|---|---|---|---|---|
| Married† | 0.791(0.755–0.830)* | 0.831(0.791–0.873)* | 0.824(0.784–0.866)* | 0.849(0.808–0.893)* | 0.845(0.804–0.888)* |
| Married‡ 1 | 0.789(0.753–0.827)* | 0.826(0.787–0.867)* | 0.818(0.779–0.860)* | 0.844(0.803–0.887)* | 0.840(0.799–0.883)* |
| Married‡ 2 | 0.784(0.742–0.827)* | 0.821(0.776–0.868)* | 0.806(0.762–0.853)* | 0.837(0.790–0.886)* | 0.837(0.790–0.887)* |
Model 1: unadjusted.
Model 2: adjusted for age and race.
Model 3: adjusted for age, race, grade, and tumor subtype.
Model 4: adjusted for age, race, grade, tumor subtype, chemotherapy, radiation (only in overall survival analysis), and surgery.
Model 5: adjusted for age, race, grade, tumor subtype, chemotherapy, radiation (only in overall survival analysis), surgery, and distant organ metastasis.
The adjusted age is a continuous variable. SHR subdistribution hazard ratio.
*p < 0.001.
†Multivariable survival analysis with metastatic breast cancer.
‡Sensitivity analysis of breast cancer-specific survival in metastatic breast cancer by excluding all patients with missing covariate data (n = 3744) and those who survived less than 1 month (n = 792) after diagnosis.
‡1: Sensitivity analysis of breast cancer-specific survival in metastatic breast cancer through classified patients with unknown cause of death as tumor-specific death.
‡2: Sensitivity analysis of breast cancer-specific survival in metastatic breast cancer by excluding all patients with missing covariate data (n = 3744), those who survived less than 1 month (n = 792) after diagnosis with an unknown cause of death.